Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice

Circulation Research

Volumn 84, Issue 7, 1999, Pages 752-762

  Leri, Annarosa ^a   Liu, Yu ^a   Wang, Xiaowei ^a   Kajstura, Jan ^a   Malhotra, Ashwani ^a   Meggs, Leonard G ^a   Anversa, Piero ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin II; Insulin like growth factor 1; mdm2; p53; Transgenic mice

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; COMPLEMENTARY DNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SOMATOMEDIN C;

ANIMAL CELL; ARTICLE; DNA BINDING; GENE OVEREXPRESSION; HEART HYPERTROPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSGENIC MOUSE;

EID: 0033574593     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.7.752     Document Type: Article

References (64)

1. Wåhlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension. 1992;19:25-32.
2. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, Slater WR, Catanese VM. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation. 1994;89:799-809.
3. Reiss K, Kajstura J, Zhang X, Li P, Szoke E, Olivetti G, Anversa P. Acute myocardial infarction leads to upregulation of the IGF-1 autocrine system, DNA replication and nuclear mitotic division in the remaining viable cardiac myocytes. Exp Cell Res. 1994;213:463-472.
4. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest. 1995;95:619-627.
5. Duerr RL, McKirnan MD, Gim RD, Clark RG, Chien KR, Ross J Jr. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation. 1996; 93:2188-2196.
6. Cheng W, Reiss K, Li P, Chun MJ, Kajstura J, Olivetti G, Anversa P. Aging does not affect the activation of the myocyte insulin-like growth factor-1 autocrine system after infarction and ventricular failure in Fischer 344 rats. Circ Res. 1996;78:536-546.
7. Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ Res. 1998;83:1-14.
8. 2+ handling and enhance cardiac performance: in vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ Res. 1996;79:227-236.
9. 2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res. 1998;83: 50-59.
10. Fuller SJ, Mynett JR, Sugden PH. Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem J. 1992;282:85-90.
11. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A. 1995;92: 8031-8035.
12. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Saccà L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809-814.
13. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 1997;100: 1991-1999.
14. Galli C, Meucci O, Scorziello A, Werge TM, Calissano P, Schettini G. Apoptosis in cerebellar granule cells is blocked by high KCl, forskolin, and IGF-1 through distinct mechanisms of action: the involvement of intracellular calcium and RNA synthesis. J Neurosci. 1995;15: 1172-1179.
15. Rodriguez-Tarduchy G, Collins MK, Garcia I, Lopez-Rivas A. Insulin-like growth factor-1 inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol. 1992;149:535-540.
16. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 1995; 55:303-306.
17. Chun SY, Billig H, Tilly JL, Furuta I, Tsafriri A, Hsueh AJ. Gonadotropin suppression of apoptosis in cultured preovulatory follicles: mediatory role of endogenous insulin-like growth factor 1. Endocrinology. 1994;135: 1845-1853.
18. Matthews CC, Feldman EL. Insulin-like growth factor 1 rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J Cell Physiol. 1996;166:323-331.
19. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R. The insulin-like growth factor 1 receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995;55: 2463-2469.
20. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894-898.
21. Jung Y-K, Miura M, Yuan J. Suppression of interleukin-1β-converting enzyme-mediated cell death by insulin-like growth factor. J Biol Chem. 1996;271:5112-5117.
22. Cigola E, Kajstura J, Li B, Meggs LG, Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res. 1997;231: 363-371.
23. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859-870.
24. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
25. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest. 1998;101:1326-1342.
26. Pierzchalski P, Reiss K, Cheng W, Cirielli C, Kajstura J, Nitahara JA, Rizk M, Capogrossi MC, Anversa P. p53 induces myocyte apoptosis via the activation of the renin-angiotensin system. Exp Cell Res. 1997;234: 57-65.
27. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9: 1799-1805.
28. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1-6.
29. Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:292-299.
30. Milczarck GJ, Martinez J, Bowden GT. p53 phosphorylation: biochemical and functional consequences. Life Sci. 1997;60:1-11.
31. Lohrum M, Scheidtmann KH. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene. 1996;12:2527-2539.
32. Momand J, Zambetti GP. Mdm-2: "Big Brother" of p53. J Cell Biochem. 1997;64:343-352.
33. Reiss K, Cheng W, Ferber A, Kajstura J, Li P, Li B, Olivetti G, Homey CJ, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci U S A. 1996;93:8630-8635.
34. Hecker D, Page G, Lohrum M, Weiland S, Scheidtmann KH. Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene. 1996;12:953-961.
35. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
36. Leri A, Liu Y, Malhotra A, Li Q, Stiegler P, Claudio PP, Giordano A, Kajstura J, Hintze TH, Anversa P. Pacing-induced heart failure in dogs enhances the expression of p53 and p53-dependent genes in ventricular myocytes. Circulation. 1998;97:194-203.
37. Zhang X, Dostal DE, Reiss K, Cheng W, Kajstura J, Li P, Huang H, Sonnenblick EH, Meggs LG, Baker KM, Anversa P. Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes. Am J Physiol. 1995;269:H1791-H1802.
38. Meng QC, Durand J, Chen Y-F, Oparil S. Simplified method for quantitation of angiotensin peptides in tissue. J Chromatogr. 1993;614:19-25.
39. O'Neill FJ, Hu Y, Chen T, Camey H. Identification of p53 unbound to T-antigen in human cells transformed by simian virus 40 T-antigen. Oncogene. 1997;14:955-965.
40. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299.
41. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299-303.
42. Momand J, Zambetti GP. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene. 1996;12: 2273-2289.
43. Atadja P, Wong H, Garkavtsev I, Veillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci U S A. 1995;92:8348-8352.
44. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Slark GR. The p53 network. J Biol Chem. 1998;273:1-4.
45. Hupp TR, Lane DP. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinase. Cold Spring Harb Symp Quant Biol. 1994;59:195-206.
46. Knippschild U, Oren M, Deppert W. Abrogation of wild type p53 mediated growth-inhibition by nuclear exclusion. Oncogene. 1996;12: 1755-1765.
47. 1 checkpoint after DNA damage. Mol Cell Biol. 1996;16:1126-1137.
48. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
49. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126-1132.
50. Piette J, Neel H, Maréchal V. Mdm2: keeping p53 under control. Oncogene. 1997;15:1001-1010.
51. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 1997;11:1974-1986.
52. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 1998;82:1111-1129.
53. Reed JC. Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia. Vitam Horm. 1997;53:99-138.
54. Oltavai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 hetorodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
55. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88:435-437.
56. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A. 1997;94:3627-3632.
57. L. Cell. 1996;87:619-628.
58. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenherg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
59. Redaelli G, Malhotra A, Li B, Li P, Sonnenblick EH, Hofmann PA, Anversa P. Effects of constitutive overexpression of insulin-like growth factor-1 on the mechanical characteristics and molecular properties of ventricular myocytes. Circ Res. 1998;82:594-603.
60. Dostal DE, Rothblum KN, Chemin MI, Cooper GR, Baker KM. Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am J Physiol. 1992;263: C838-C850.
61. Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am J Physiol. 1992;263:C851-C863.
62. Liu Y, Leri A, Li B, Wang X, Cheng W, Kajstura J, Anversa P. Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes. Circ Res. 1998;82:1145-1159.
63. Pfeffer MA, Braunwald E, and the SOLVD Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327: 669-677.
64. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.